TENAX THERAPEUTICS, INC. (TENX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
TENAX THERAPEUTICS, INC. (TENX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 d251626dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 FIRST AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “ Amendment ”), is made as of June 29, 2026 by and between Tenax Therapeutics, Inc., a Delaware corporation, wit
How this was made
The 30-second read
Why it matters
The amendment updates (1) annual bonus calculation (including no cap above 100% of goals) and (2) termination benefits, especially during a change-in-control window (18 months base salary, target bonus proration, full equity vesting, and 18 months COBRA reimbursement).
Market read
This is a governance/compensation disclosure; it may influence sentiment but does not provide new clinical, revenue, or regulatory catalysts in the provided text.
What to watch
Traders may overreact to severance optics; the more relevant question is whether the amendment signals leadership stability or upcoming strategic events (not disclosed in the excerpt).
Background
The filing is an SEC Form 8-K (Item 5.02) attaching a First Amendment to the CEO executive employment agreement dated June 29, 2026.
Ticker impact
Tenax Therapeutics amends CEO Christopher Giordano’s employment agreement, changing bonus mechanics and adding/clarifying change-in-control termination benefits.
Limited near-term impact; any reaction is likely sentiment/overhang related rather than fundamentals.
This is a corporate governance/compensation filing with no operational or financial guidance, but it can affect perceived cash burn and governance optics.
Market effects
Minimal; executive comp changes are company-specific and not a sector-wide catalyst.
None indicated.
None indicated.
Counterpoint
The change-in-control package may be standard for biotech CEOs and may not materially affect valuation if Tenax’s cash runway and burn are unchanged.
Key entities
- companyTenax Therapeutics, Inc.
Subject of the 8-K; amends CEO employment agreement terms.
- executiveChristopher Thomas Giordano
CEO whose employment agreement is amended; benefits and bonus mechanics are revised.
